Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLK NASDAQ:BPMC NASDAQ:GLPG NASDAQ:IONS NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLKAllakos$0.33$0.33$0.22▼$1.56$29.74M0.151.24 million shsN/ABPMCBlueprint Medicines$129.48+0.2%$119.38$73.04▼$129.65$8.36B0.891.54 million shs2.98 million shsGLPGGalapagos$31.14+1.6%$28.55$22.36▼$31.39N/A0.07256,643 shs306,541 shsIONSIonis Pharmaceuticals$41.76-1.0%$37.30$23.95▼$52.34$6.71B0.231.62 million shs1.27 million shsTGTXTG Therapeutics$37.91-3.3%$36.33$16.65▼$46.48$6.22B1.912.85 million shs1.79 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLKAllakos0.00%0.00%0.00%+0.95%-60.04%BPMCBlueprint Medicines+0.14%+0.10%+0.96%+52.98%+13.20%GLPGGalapagos+1.36%+0.56%+9.81%+24.33%+13.56%IONSIonis Pharmaceuticals-1.40%-0.50%+16.65%+48.49%-12.07%TGTXTG Therapeutics+0.90%+4.04%+11.97%+2.27%+77.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLKAllakos3.3852 of 5 stars3.20.00.04.70.02.51.3BPMCBlueprint Medicines1.0832 of 5 stars2.12.00.00.02.30.80.6GLPGGalapagos0.5979 of 5 stars0.84.00.00.02.70.00.6IONSIonis Pharmaceuticals4.4718 of 5 stars4.42.00.03.02.13.30.6TGTXTG Therapeutics3.4049 of 5 stars2.40.00.03.51.62.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLKAllakos 2.33Hold$3.00811.58% UpsideBPMCBlueprint Medicines 2.24Hold$128.25-0.95% DownsideGLPGGalapagos 1.50Reduce$25.33-18.65% DownsideIONSIonis Pharmaceuticals 2.76Moderate Buy$57.1336.81% UpsideTGTXTG Therapeutics 2.80Moderate Buy$43.8015.54% UpsideCurrent Analyst Ratings BreakdownLatest ALLK, BPMC, IONS, GLPG, and TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025TGTXTG TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$37.007/1/2025IONSIonis PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$51.00 ➝ $57.006/26/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/17/2025BPMCBlueprint MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$143.00 ➝ $129.006/12/2025IONSIonis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$45.00 ➝ $48.006/5/2025BPMCBlueprint MedicinesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$102.00 ➝ $129.006/5/2025BPMCBlueprint MedicinesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$88.00 ➝ $129.006/4/2025BPMCBlueprint MedicinesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell ➝ Hold$83.00 ➝ $129.006/3/2025BPMCBlueprint MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$132.006/3/2025BPMCBlueprint MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/3/2025BPMCBlueprint MedicinesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLKAllakosN/AN/AN/AN/A$1.93 per shareN/ABPMCBlueprint Medicines$508.82M16.43N/AN/A$4.70 per share27.55GLPGGalapagos$298.31MN/A$0.74 per share42.23$47.57 per shareN/AIONSIonis Pharmaceuticals$705M9.43N/AN/A$3.73 per share11.20TGTXTG Therapeutics$329M18.29$0.12 per share326.68$1.43 per share26.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLKAllakos-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%8/6/2025 (Estimated)BPMCBlueprint Medicines-$67.09M-$2.47N/A199.20N/A-27.70%-64.60%-17.22%7/30/2025 (Estimated)GLPGGalapagos$80.16MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)IONSIonis Pharmaceuticals-$453.90M-$2.99N/AN/AN/A-63.65%-91.85%-15.77%7/30/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.24157.9637.91N/A10.13%18.88%7.05%8/5/2025 (Estimated)Latest ALLK, BPMC, IONS, GLPG, and TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025BPMCBlueprint Medicines-$0.54N/AN/AN/A$171.34 millionN/A8/6/2025Q2 2025ALLKAllakos-$0.24N/AN/AN/AN/AN/A8/5/2025Q2 2025TGTXTG Therapeutics$0.27N/AN/AN/A$147.76 millionN/A7/30/2025Q2 2025IONSIonis Pharmaceuticals$0.19N/AN/AN/A$270.90 millionN/A7/23/2025Q2 2025GLPGGalapagos-$0.34N/AN/AN/A$80.13 millionN/A5/7/2025Q1 2025TGTXTG Therapeutics$0.19$0.03-$0.16$0.03$117.07 million$120.86 million5/1/2025Q1 2025BPMCBlueprint Medicines-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million4/30/2025Q1 2025IONSIonis Pharmaceuticals-$1.07-$0.93+$0.14-$0.93$144.31 million$132.00 million4/23/2025Q1 2025GLPGGalapagos-$0.23-$2.47-$2.24-$2.45$72.22 million$97.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLKAllakosN/AN/AN/AN/AN/ABPMCBlueprint MedicinesN/AN/AN/AN/AN/AGLPGGalapagosN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLKAllakosN/A6.086.08BPMCBlueprint Medicines1.012.802.75GLPGGalapagosN/A7.957.86IONSIonis Pharmaceuticals2.639.669.62TGTXTG Therapeutics1.034.023.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLKAllakos84.64%BPMCBlueprint MedicinesN/AGLPGGalapagos32.46%IONSIonis Pharmaceuticals93.86%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipALLKAllakos16.12%BPMCBlueprint Medicines4.21%GLPGGalapagos2.91%IONSIonis Pharmaceuticals2.60%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLKAllakos19090.38 million74.94 millionOptionableBPMCBlueprint Medicines64064.58 million61.86 millionOptionableGLPGGalapagos1,310N/AN/AOptionableIONSIonis Pharmaceuticals1,069159.16 million155.02 millionOptionableTGTXTG Therapeutics290158.76 million141.86 millionOptionableALLK, BPMC, IONS, GLPG, and TGTX HeadlinesRecent News About These CompaniesTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Hussman Strategic Advisors Inc.July 18 at 10:39 AM | marketbeat.comJackson Creek Investment Advisors LLC Has $1.40 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)July 18 at 10:08 AM | marketbeat.comEdgestream Partners L.P. Increases Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 18 at 5:02 AM | marketbeat.comSigma Planning Corp Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 17 at 5:25 AM | marketbeat.comBank of New York Mellon Corp Cuts Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 15 at 3:35 AM | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Upgraded to Hold at The Goldman Sachs GroupJuly 13, 2025 | americanbankingnews.comTG Therapeutics (TGTX) Gets a Hold from Goldman SachsJuly 12, 2025 | theglobeandmail.comBanque Pictet & Cie SA Acquires Shares of 13,151 TG Therapeutics, Inc. (NASDAQ:TGTX)July 11, 2025 | marketbeat.comTG Therapeutics Joins Rank Of Stocks With RS Ratings Over 90July 10, 2025 | msn.comTG Therapeutics Joins Elite List Of Stocks With 95-Plus Composite RatingJuly 10, 2025 | msn.comTG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from AnalystsJuly 10, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Earns Neutral Rating from Analysts at The Goldman Sachs GroupJuly 10, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Position Increased by Allspring Global Investments Holdings LLCJuly 9, 2025 | marketbeat.comAxsome Therapeutics Sees Relative Strength Rating Climb To 79July 8, 2025 | msn.comPenserra Capital Management LLC Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 8, 2025 | marketbeat.comPrincipal Financial Group Inc. Increases Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 8, 2025 | marketbeat.comNew York State Teachers Retirement System Boosts Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 7, 2025 | marketbeat.comBraun Stacey Associates Inc. Has $19.82 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)July 5, 2025 | marketbeat.comTG Therapeutics, Inc. (TGTX) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comJim Cramer on TG Therapeutics: “You Should Buy the Stock”July 2, 2025 | insidermonkey.comKymera Therapeutics Shows Market Leadership With Jump To 93 RS RatingJuly 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendAnalysts Supercharge AMD Stock Ahead of Q2 AI CatalystBy Thomas Hughes | June 26, 2025View Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst2 Under the Radar Space & Defense Stocks With Huge PotentialBy Leo Miller | July 1, 2025View 2 Under the Radar Space & Defense Stocks With Huge Potential3 Stocks to Buy Ahead of the Upcoming Earnings SeasonBy Chris Markoch | July 11, 2025View 3 Stocks to Buy Ahead of the Upcoming Earnings SeasonPelosi Makes Big Bet on Broadcom—Here’s Why It MattersBy Gabriel Osorio-Mazilli | July 15, 2025View Pelosi Makes Big Bet on Broadcom—Here’s Why It MattersALLK, BPMC, IONS, GLPG, and TGTX Company DescriptionsAllakos NASDAQ:ALLKAllakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.Blueprint Medicines NASDAQ:BPMC$129.48 +0.20 (+0.15%) Closing price 07/17/2025 05:56 PM EasternExtended Trading$129.48 0.00 (0.00%) As of 07/17/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Galapagos NASDAQ:GLPG$31.14 +0.48 (+1.57%) Closing price 04:00 PM EasternExtended Trading$31.14 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Ionis Pharmaceuticals NASDAQ:IONS$41.76 -0.41 (-0.97%) Closing price 04:00 PM EasternExtended Trading$41.76 +0.01 (+0.01%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.TG Therapeutics NASDAQ:TGTX$37.91 -1.28 (-3.27%) Closing price 04:00 PM EasternExtended Trading$38.16 +0.25 (+0.65%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
